Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a DDI with OATP1B/CYP3A Inhibitors in HER2-Expressing Solid Tumors
jRCT2080223734Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in Non-hematologic malignancy, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Effect of ritonavir on DS-8201a pharmacokinetics and Effect of itraconazole on DS-8201a pharmacokinetics. Started Nov 2017; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223734.